Less frequent mammographic surveillance non-inferior compared with annual mammograms after diagnosis of breast cancer in women aged 50 years or older

 Results of Mammo-50, a randomized phase III trial conducted across the United Kingdom on women aged 50 or older was recently published in The Lancet.  Findings from Mammo-50 indicate that women 50 years or older when diagnosed with breast cancer "who have undergone annual mammographic surveillance for 3 years post diagnosis...[and who] show no signs of recurrence, can safely have less frequent mammograms."  The authors further state that this evidence may result in changes to guidelines, both within the U.K. and globally as well. 

To learn more about the Mammo-50 trial, click here. 

Sources mentioned: 

• Dunn JA, Donnelly P, Elbeltagi N, et al. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. The Lancet 2025;405(10476):396–407.
• 
  
• Mann RM. Rethinking surveillance after breast cancer. The Lancet 2025;405(10476):356-358.